Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124147813 | 12414781 | 3 | F | 2013 | 20160803 | 20160529 | 20160810 | EXP | PHHY2015BR142408 | NOVARTIS | 0.00 | M | Y | 70.00000 | KG | 20160810 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124147813 | 12414781 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO | SC733 | 21008 | 30 | MG | VIAL | /month | |||||
| 124147813 | 12414781 | 2 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | SA822 | 0 | 10 | MG | TABLET | QD | |||||
| 124147813 | 12414781 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 10 MG, QD | Y | 0 | 10 | MG | TABLET | QD | |||||
| 124147813 | 12414781 | 4 | C | LOSARTAN. | LOSARTAN | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124147813 | 12414781 | 1 | Pancreatic neuroendocrine tumour |
| 124147813 | 12414781 | 2 | Pancreatic neuroendocrine tumour |
| 124147813 | 12414781 | 3 | Metastases to spine |
| 124147813 | 12414781 | 4 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124147813 | 12414781 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124147813 | 12414781 | Abdominal distension | |
| 124147813 | 12414781 | Ageusia | |
| 124147813 | 12414781 | Blood cholesterol decreased | |
| 124147813 | 12414781 | Blood test abnormal | |
| 124147813 | 12414781 | Decreased appetite | |
| 124147813 | 12414781 | Diarrhoea | |
| 124147813 | 12414781 | Dysentery | |
| 124147813 | 12414781 | Eating disorder | |
| 124147813 | 12414781 | Epistaxis | |
| 124147813 | 12414781 | Expired product administered | |
| 124147813 | 12414781 | Flatulence | |
| 124147813 | 12414781 | Functional gastrointestinal disorder | |
| 124147813 | 12414781 | Malaise | |
| 124147813 | 12414781 | Malignant neoplasm progression | |
| 124147813 | 12414781 | Memory impairment | |
| 124147813 | 12414781 | Metastases to gastrointestinal tract | |
| 124147813 | 12414781 | Metastases to liver | |
| 124147813 | 12414781 | Metastases to lung | |
| 124147813 | 12414781 | Metastases to spine | |
| 124147813 | 12414781 | Nervous system disorder | |
| 124147813 | 12414781 | Nervousness | |
| 124147813 | 12414781 | Pain | |
| 124147813 | 12414781 | Stomatitis | |
| 124147813 | 12414781 | Therapeutic response decreased | |
| 124147813 | 12414781 | Urine analysis abnormal | |
| 124147813 | 12414781 | Urine uric acid increased | |
| 124147813 | 12414781 | Vitiligo | |
| 124147813 | 12414781 | Weight decreased | |
| 124147813 | 12414781 | Weight increased | |
| 124147813 | 12414781 | Yellow skin |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124147813 | 12414781 | 1 | 201108 | 0 | ||
| 124147813 | 12414781 | 2 | 201507 | 0 | ||
| 124147813 | 12414781 | 3 | 2014 | 0 | ||
| 124147813 | 12414781 | 4 | 2011 | 0 |